EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Executive Summary
House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.
You may also be interested in...
Califf Likely To Find Many Familiar Problems Upon Return To US FDA Helm
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.
Robert Califf Likely To Find Many Familiar Problems Upon His Return To US FDA
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.
Naloxone Sponsor Steps In Pricing Hole Disputing FDA's Cost Estimates
While arguing that US FDA overestimated inflation and fill rates when calculating annual cost of co-prescribing naloxone with opioids, Adapt Pharma opened door to pricing pledge questions that the Narcan sponsor could not answer.